Researchers report TNFR1 signaling drives intestinal stem cell aging via impaired fatty acid oxidation

A study in mice establishes that systemic TNF-mediated TNFR1 signaling drives intestinal stem cell aging by impairing mitochondrial fatty acid oxidation, a phenotype reversed in vivo by systemic anti-inflammatory or mitochondrial-targeted therapies.

Researchers reported in Nature Aging that tumor necrosis factor (TNF)-mediated signaling through epithelial tumor necrosis factor receptor 1 (TNFR1) acts as a systemic progeronic driver of intestinal stem cell (ISC) aging.

Using heterochronic parabiosis, the team demonstrated that exposure to an aged systemic environment propagates the ISC aging phenotype—marked by an approximate 30% reduction in organoid-forming capacity and decreased in vivo proliferation—from old to young mice.

Intestinal epithelial-specific TNFR1 knockout protected young mice from the progeronic effects of the old circulatory environment during heterochronic parabiosis.

Bulk RNA sequencing revealed that exposing young organoids to TNF (at 10 ng/mL and 50 ng/mL) triggered a dose-dependent downregulation of key fatty acid oxidation (FAO) genes (including Cpt1a, Fabp1, Fabp2, Pparg, and Ppara) and compromised maximal oxygen consumption rates.

Systemic administration of anti-inflammatory therapies, including rapamycin, salicylate, aspirin, and neutralizing monoclonal antibodies targeting TNF or IFNγ, restored organoid-forming capacity in aged mice, whereas the gut-confined anti-inflammatory 5-ASA had no effect.

Targeted metabolomic flux analysis using U-13C16-palmitic acid confirmed that chronic salicylate treatment in aged mice enhanced palmitate uptake and citrate labeling in crypts, routing fatty acids directly into the tricarboxylic acid cycle.

Although local stem cell niche dysregulation is well documented, this study provides concrete evidence that systemic circulatory factors are primary drivers of localized tissue stem cell exhaustion.

The discovery directly links systemic 'inflammaging' to cell-autonomous metabolic failure, showing that TNFR1 signaling actively suppresses the mitochondrial lipid metabolic programs required for ISC self-renewal and epithelial regeneration.

The selective rescue of aged crypt function by systemic NSAIDs and rapamycin, contrasted with the failure of gut-confined 5-ASA, suggests that successful clinical rejuvenation of localized tissue niches requires addressing systemic inflammatory tone rather than purely localized symptoms.

These findings validate therapeutic programs targeting systemic inflammatory pathways, notably TNF and mTOR, to counter age-related barrier degradation and epithelial decline.

The research provides robust mechanistic support for developers using mitochondrial dynamics and metabolic reprogramming technologies to restore stem cell function, showing that mitochondrial fusion activators like MASM7 can directly rescue crypt budding capacity in aged tissues.

For companies utilizing target-discovery platforms in cellular senescence and mucosal repair, the study highlights a translationally accessible path to address stem cell exhaustion via systemic metabolic targets rather than complex genetic interventions.

Preclinical evaluations of clinical-stage systemic anti-TNF or anti-IFNγ biologics for restoring epithelial resilience in aged patients following mucosal injuries, such as chemotherapy or radiation-induced mucositis.

Further studies investigating whether systemic clearance of senescent cells (senolytics) can reduce circulating TNF levels sufficiently to restore endogenous TNFR1-mediated fatty acid oxidation in mucosal tissues.